Boston Therapeutics (BTHE) 0.4287 $BTHE
Boston Therapeutics to Present at Rodman & Renshaw Annual Global Investment Conference on September 10, 2014
Marketwire - Fri Sep 05, 7:37AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), developer of complex carbohydrate therapeutics to treat diabetes, announced that David Platt, Ph.D., Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 10, 2014 at 2:55 PM EDT. Dr. Platt intends to provide an update on the Company's business activities including its development of compounds using complex carbohydrate chemistry to develop a new generation of alpha Glucosidase inhibitors to treat diabetes non-systemically. Dr. Platt's presentation will be posted to the Company's website: www.bostonti.com.
Boston Therapeutics concludes enrollment of Type 2 diabetes patients in Phase IIb Study of BTI-320 in the US
M2 - Thu Aug 21, 7:35AM CDT
Carbohydrate therapeutic company Boston Therapeutics (OTCQB:BTHE) said on Wednesday that it has closed the admission of Type 2 diabetes patients in the US under its Phase IIb clinical study (SD-002) of BTI-320.
Boston Therapeutics Completes Enrollment of Patients With Type 2 Diabetes in Phase IIb Study on BTI-320 in the U.S.
Marketwire - Wed Aug 20, 7:12AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, has completed enrollment of its Phase IIb clinical study on BTI-320 in the United States. The study, SD-002, is being conducted by Accumed Research Associates in Garden City, NY.
Boston Therapeutics Appoints Noted Diabetes Specialist Jaime A. Davidson, M.D. to Its Medical Advisory Board
Marketwire - Mon Aug 18, 6:26AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, has appointed noted diabetes specialist Jaime A. Davidson, M.D. to its Medical Advisory Board.
Boston Therapeutics Reports Corporate Update and Financial Results for the Second Quarter Ended June 30, 2014
Marketwire - Fri Aug 08, 9:58AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the second quarter and six months ended June 30, 2014.
Boston Therapeutics Expands Medical Advisory Board
Marketwire - Tue Aug 05, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrate therapeutics to treat diabetes, has expanded its Medical Advisory Board with the appointments of Meng H Tan, M.D., Philip Raskin, M.D., and Charles M. Clark, Jr., M.D. as advisors.
Boston Therapeutics to Sponsor Symposium at American Chemical Society's Fall National Meeting in San Francisco
Marketwire - Wed Jul 30, 5:30AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, is sponsoring a symposium to be held at the American Chemical Society's Fall National Meeting in San Francisco on Monday, August 11.
Boston Therapeutics Appoints Zbigniew J. Witczak, Ph.D., to Its Scientific Advisory Board
Marketwire - Tue Jul 29, 5:30AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Zbigniew J. Witczak, Ph.D. to its Scientific Advisory Board (SAB). This brings the total number of Scientific Advisory Board members to six.
Boston Therapeutics Appoints Benjamin Rivnay, Ph.D. to Chief Scientist
Marketwire - Wed Jul 09, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the Company's science and technology. He will serve as the primary liaison to the Company's Medical Advisory Board and report to Rom E. Eliaz, Ph.D., chairman of the Board of Directors' Scientific Advisory Committee.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Jun 19, 10:53AM CDT
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"
TM) television program will feature three emerging growth companies on Fox Business nationwide on Thursday, June 19, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, June 21, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, June 22, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday June 22, 2014 at 3:30 p.m. HKT.
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Boston Therapeutics, Inc.
Marketwire - Thu Mar 27, 8:32AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on Boston Therapeutics, Inc. (OTCQB: BTHE). The full 60-page report is available on Crystal Research Associates' website at www.crystalra.com.
Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Marketwire - Mon Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the fourth quarter and year ended December 31, 2013.
Boston Therapeutics to launch Phase II clinical study of BTI-320 in the US in Type 2 diabetes patients
M2 - Wed Mar 05, 6:16AM CST
Complex carbohydrate company Boston Therapeutics (OTCQB:BTHE) said on Tuesday that it will start clinical study of BTI-320 in the US upon Institutional Review Board (IRB) approval.
Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.
Marketwire - Tue Mar 04, 6:20AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , an innovative developer of compounds that address diabetes using complex carbohydrate chemistry, has received Institutional Review Board (IRB) approval to initiate a clinical study of BTI-320 (previously named PAZ320) in the United States. The Company expects the trial to last for approximately three months. The U.S.-based trial is intended to mirror the Company's study of BTI-320 currently enrolling patients in France.
Boston Therapeutics Appoints Larry K. Ellingson, Former Chair of the American Diabetes Association, as Chair of Its Scientific Advisory Board
Marketwire - Tue Feb 25, 6:02AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Larry K. Ellingson as Chairman of its Scientific Advisory Board, effective immediately.
Boston Therapeutics Signs Agreement to Market SugarDown(R) in the U.S.
Marketwire - Tue Feb 11, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has signed a consulting agreement with Generosus Advisors, LLC and Fortified Management Group, LLC to market SugarDown(R) in the United States on a non-exclusive basis. The marketing effort will be conducted via the Help Now Network (HNN), a healthcare marketing company and its affiliates. SugarDown(R) is a dietary supplement that is indicated in its functional claims to support healthy blood sugar and has shown in clinical studies to reduce after meal sugar spikes.
Provide Good Service and 'Pirates' Will Go
All Africa Global Media - Fri Dec 20, 10:05AM CST
"What comes first is good service and customers follow. We cannot invert these natural laws of commerce to protect incompetent managers at the NRZ."
Boston Therapeutics Inc concludes USD3.5m private placement
M2 - Tue Sep 10, 7:35AM CDT
Drug company Boston Therapeutics Inc (OTCQB:BTHE) revealed on Monday the completion of a private placement of common stock and warrants for total gross proceeds of USD3.5m.
Boston Therapeutics Closes on Approximately $3.5 Million in Private Placement of Common Stock and Warrants
Marketwire - Mon Sep 09, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of drugs based on complex carbohydrate chemistry to treat diabetes and inflammatory diseases, has closed on total gross proceeds of approximately $3.5 million to date from the private placement offering of common stock and warrants to existing and new accredited investors.
Boston Therapeutics Reports Positive Phase II Results of PAZ320 Are Published in July/August Issue of Endocrine Practice
Marketwire - Wed Sep 04, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a developer of complex carbohydrates to treat diabetes and inflammatory diseases, reports positive results from a Phase II clinical trial that evaluated the safety and efficacy of PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes is published in the July/August issue of Endocrine Practice, a peer-reviewed journal.
Boston Therapeutics to Present at Rodman & Renshaw Annual Global Investment Conference on September 10, 2014
Marketwire - Fri Sep 05, 7:37AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), developer of complex carbohydrate therapeutics to treat diabetes, announced that David Platt, Ph.D., Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 10, 2014 at 2:55 PM EDT. Dr. Platt intends to provide an update on the Company's business activities including its development of compounds using complex carbohydrate chemistry to develop a new generation of alpha Glucosidase inhibitors to treat diabetes non-systemically. Dr. Platt's presentation will be posted to the Company's website: www.bostonti.com.
Boston Therapeutics concludes enrollment of Type 2 diabetes patients in Phase IIb Study of BTI-320 in the US
M2 - Thu Aug 21, 7:35AM CDT
Carbohydrate therapeutic company Boston Therapeutics (OTCQB:BTHE) said on Wednesday that it has closed the admission of Type 2 diabetes patients in the US under its Phase IIb clinical study (SD-002) of BTI-320.
Boston Therapeutics Completes Enrollment of Patients With Type 2 Diabetes in Phase IIb Study on BTI-320 in the U.S.
Marketwire - Wed Aug 20, 7:12AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, has completed enrollment of its Phase IIb clinical study on BTI-320 in the United States. The study, SD-002, is being conducted by Accumed Research Associates in Garden City, NY.
Boston Therapeutics Appoints Noted Diabetes Specialist Jaime A. Davidson, M.D. to Its Medical Advisory Board
Marketwire - Mon Aug 18, 6:26AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, has appointed noted diabetes specialist Jaime A. Davidson, M.D. to its Medical Advisory Board.
Boston Therapeutics Reports Corporate Update and Financial Results for the Second Quarter Ended June 30, 2014
Marketwire - Fri Aug 08, 9:58AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the second quarter and six months ended June 30, 2014. Boston Therapeutics Expands Medical Advisory Board
Marketwire - Tue Aug 05, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes, has expanded its Medical Advisory Board with the appointments of Meng H Tan, M.D., Philip Raskin, M.D., and Charles M. Clark, Jr., M.D. as advisors. Boston Therapeutics to Sponsor Symposium at American Chemical Society's Fall National Meeting in San Francisco
Marketwire - Wed Jul 30, 5:30AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, is sponsoring a symposium to be held at the American Chemical Society's Fall National Meeting in San Francisco on Monday, August 11.
Boston Therapeutics Appoints Zbigniew J. Witczak, Ph.D., to Its Scientific Advisory Board
Marketwire - Tue Jul 29, 5:30AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Zbigniew J. Witczak, Ph.D. to its Scientific Advisory Board (SAB). This brings the total number of Scientific Advisory Board members to six.
Boston Therapeutics Appoints Benjamin Rivnay, Ph.D. to Chief Scientist
Marketwire - Wed Jul 09, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the Company's science and technology. He will serve as the primary liaison to the Company's Medical Advisory Board and report to Rom E. Eliaz, Ph.D., chairman of the Board of Directors' Scientific Advisory Committee.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Jun 19, 10:53AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature three emerging growth companies on Fox Business nationwide on Thursday, June 19, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, June 21, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, June 22, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday June 22, 2014 at 3:30 p.m. HKT. Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Boston Therapeutics, Inc.
Marketwire - Thu Mar 27, 8:32AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on Boston Therapeutics, Inc. (OTCQB: BTHE). The full 60-page report is available on Crystal Research Associates' website at www.crystalra.com.
Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Marketwire - Mon Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the fourth quarter and year ended December 31, 2013. Boston Therapeutics to launch Phase II clinical study of BTI-320 in the US in Type 2 diabetes patients
M2 - Wed Mar 05, 6:16AM CST
Complex carbohydrate company Boston Therapeutics (OTCQB:BTHE) said on Tuesday that it will start clinical study of BTI-320 in the US upon Institutional Review Board (IRB) approval.
Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.
Marketwire - Tue Mar 04, 6:20AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of compounds that address diabetes using complex carbohydrate chemistry, has received Institutional Review Board (IRB) approval to initiate a clinical study of BTI-320 (previously named PAZ320) in the United States. The Company expects the trial to last for approximately three months. The U.S.-based trial is intended to mirror the Company's study of BTI-320 currently enrolling patients in France. Boston Therapeutics Appoints Larry K. Ellingson, Former Chair of the American Diabetes Association, as Chair of Its Scientific Advisory Board
Marketwire - Tue Feb 25, 6:02AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Larry K. Ellingson as Chairman of its Scientific Advisory Board, effective immediately. Boston Therapeutics Signs Agreement to Market SugarDown(R) in the U.S.
Marketwire - Tue Feb 11, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has signed a consulting agreement with Generosus Advisors, LLC and Fortified Management Group, LLC to market SugarDown(R) in the United States on a non-exclusive basis. The marketing effort will be conducted via the Help Now Network (HNN), a healthcare marketing company and its affiliates. SugarDown(R) is a dietary supplement that is indicated in its functional claims to support healthy blood sugar and has shown in clinical studies to reduce after meal sugar spikes. Provide Good Service and 'Pirates' Will Go
All Africa Global Media - Fri Dec 20, 10:05AM CST
"What comes first is good service and customers follow. We cannot invert these natural laws of commerce to protect incompetent managers at the NRZ."
Boston Therapeutics Inc concludes USD3.5m private placement
M2 - Tue Sep 10, 7:35AM CDT
Drug company Boston Therapeutics Inc (OTCQB:BTHE) revealed on Monday the completion of a private placement of common stock and warrants for total gross proceeds of USD3.5m.
Boston Therapeutics Closes on Approximately $3.5 Million in Private Placement of Common Stock and Warrants
Marketwire - Mon Sep 09, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of drugs based on complex carbohydrate chemistry to treat diabetes and inflammatory diseases, has closed on total gross proceeds of approximately $3.5 million to date from the private placement offering of common stock and warrants to existing and new accredited investors. Boston Therapeutics Reports Positive Phase II Results of PAZ320 Are Published in July/August Issue of Endocrine Practice
Marketwire - Wed Sep 04, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrates to treat diabetes and inflammatory diseases, reports positive results from a Phase II clinical trial that evaluated the safety and efficacy of PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes is published in the July/August issue of Endocrine Practice, a peer-reviewed journal. 
